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Abstract
Background: Crude extracts of Chelidonium majus, and also purified compounds derived from
crude extracts of this plant, have been reported to exhibit anti-viral, anti-inflammatory, anti-tumor
and anti-microbial properties both in vitro and in vivo. Chelidonium is a homeopathic drug routinely
used against various liver disorders including cancer in humans. Two potencies of Chelidonium
(Ch-30, Ch-200) have been tested for their possible anti-tumor and enzyme modulating activities
in liver and anti-clastogenic effects during p-DAB-induced hepatocarcinogenesis in mice compared
to suitable controls.
Methods: Several cytogenetic and enzymatic protocols were used at three fixation intervals; at 60
d a y s ,  9 0  d a y s  a n d  1 2 0  d a y s  o f  t r e a t m e n t .  D i f f e r e n t  s e t s  o f  h e a l t h y  m i c e  w e r e  f e d :  i )
hepatocarcinogen, p-DAB plus phenobarbital (PB), ii) only PB, iii) neither p-DAB nor PB (normal
control). One set of mice fed with p-DAB plus PB was also fed Ch-30 (iv) and another set Ch-200
(v). All standard currently used methods were adopted for cytogenetical preparations and for the
enzyme assays.
Results: All group (i) mice developed tumors in liver at all fixation intervals, while none of group
(ii) and (iii) mice developed any tumors. About 40% mice in group (iv) and group (v) did not show
tumor nodules in their liver. Feeding of Chelidonium to group (iv) and (v) mice reduced genotoxic
effects to a significant extent (p < 0.05 to p < 0.001).
Conclusion:  The homeopathic drug Chelidonium exhibited anti-tumor and anti-genotoxic
activities and also favorably modulated activities of some marker enzymes. Microdoses of
Chelidonium may be effectively used in combating liver cancer.
Background
Chelidonium majus L. (Papaveraceae) is a plant of great in-
terest for its use in various diseases in European countries
and in Chinese herbal medicines. Crude extracts of vari-
ous parts such as the root, shoot and leaves have been re-
ported to have several isoquinoline alkaloids, such as,
sanguinarine, chelidonine, chelerythrine, berberine and
coptisisine. Both crude extracts of C. majus and purified
compounds derived from it have been reported to exhibit
interesting anti-viral, anti-inflammatory, anti-tumor and
anti-microbial properties both in vitro and in vivo[1–3].
Besides, inhibitory effect of Chelidonium majus herb extract
has been reported on growth of keratinocytes in human,
and on lipoxygenase activity in mice [4] while stimulatory
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effect has been reported on bile acid independent flow in
isolated perfused rat liver [5].
In the homeopathic mode of treatment, various micro
doses (potencies) of Chelidonium herb extract are rou-
tinely used against several forms of liver disorders, includ-
ing liver cancer [6] with good effect. But, to our
knowledge, whether ultra-low doses of Chelidonium majus,
namely, Chelidonium-30 (Ch-30) and Chelidonium-200
(Ch-200), could also have similar anti-tumor or anti-gen-
otoxic activities had not been experimentally tested so far
in mice in vivo. The present investigation was therefore un-
dertaken primarily to examine if Ch-30 and Ch-200, pre-
pared as per homeopathic procedure, could show i) anti-
tumor activity in liver, ii) anti-clastogenic effect in bone
marrow cells, iii) protective/repair ability on sperm heads,
and iv) ameliorating effects in the activities of some mark-
er enzymes like acid and alkaline phosphatases, and per-
oxidase in various tissues during azo dye induced
hepatocarcinogenesis in mice.
Materials and methods
Materials
An inbred strain of Swiss albino mice (Mus musculus),
reared and maintained in the animal house of the Depart-
ment of Zoology, (under the supervision of the Animal
Welfare Committee), Kalyani University, served as materi-
als for the present study. Mice were provided food and wa-
ter ad libitum. The food was made of wheat, gram and
powdered milk without any animal protein supplement.
With due permission from the Animal Welfare Commit-
tee, Kalyani University, which also oversees ethical issues
of animal experimentation, the present investigation was
undertaken. A group of 25 healthy mice weighing be-
tween 25–30 grams were used for each of the three long
term fixation intervals viz. 60, 90 and 120 days. Each
group was further divided into five different sets consist-
ing of five mice each. The first set of mice were allowed
normal low protein diet mixed with 0.06% p-DAB (Sig-
ma, D-6760), a known "initiator" of hepatocarcinoma,
and water ad libitum, till 30 days after which the water was
replaced with 0.05% aqueous solution of PB, a known
"promoter", till they were sacrificed. The second set of
mice were provided with low protein diet without p-DAB
and 0.05% aqueous solution of PB instead of pure water
after one month as in group (i) till they were sacrificed.
For the third set of mice the low protein diet was neither
mixed with p-DAB nor water was replaced with PB. The
third set served as negative control. The fourth set of mice
were given p-DAB and PB in the same way as that of the
first group but were also fed 0.06 ml of stock solution of
the drug-Ch-30 thrice a day (6 A.M, 12 Noon, 6 P.M) from
first day onward of p-DAB feeding, for seven days, and
then twice a day (6 AM, 6 PM) till they were sacrificed. In
the fifth set of mice the feeding of p-DAB, PB and Ch-200
followed the same manner as that of the fourth set of
mice, except that the drug was fed twice a day (6AM, 6PM)
all along till they were sacrificed.
Preparation of the potentized homeopathic drug
The two potencies of Chelidonium, procured from "HAP-
CO", 165, Bipin Behari Ganguli Street, Kolkata, were pre-
pared as per the standard procedure of homoeopathic
drug preparation. The dry drug material of Chelidonium
majus (whole plant) was extracted in 44% ethyl alcohol
(i.e. the "mother tincture"). 1 ml of the mother tincture
was subsequently diluted with 99 ml HPI approved sol-
vent (IP 96/HPI grade ethyl alcohol) and "succussed" 10
times to make the potency 1. The potency 2 was similarly
made by diluting 1 ml of potency 1 with 99 ml of ethyl al-
cohol and giving 10 jerks, and the procedure was repeated
to get the microdoses of Ch-30 and Ch-200.
Preparation of stock solution of the drug
1 ml each of Ch-30 and Ch-200 was finally diluted sepa-
rately with 20 ml of double distilled water to make the
stock solution of Ch-30 and Ch-200, respectively.
Feeding procedure and dose
Each mouse was fed 1 drop (0.06 ml) of either Ch-30 or
Ch-200 from the stock solutions at a time with the aid of
a fine pipette.
Cytogenetic assay
Mice were intra-peritonially injected with 0.03% colchi-
cine @ 1 ml/100 gm body weight 1 hr and 30 min before
sacrifice. Marrow of the femur was flushed in 1% sodium
citrate solution at 37°C and fixed in acetic acid/ethanol
(1:3). Slides were prepared by the conventional flame dry-
ing technique followed by Giemsa staining for scoring
bone marrow chromosome aberrations. A total of 500
bone marrow cells were observed, 100 from each of 5
mice of a set.
For micronucleus (MN) preparation, a part of the suspen-
sion of bone marrow cells in 1% sodium citrate was
smeared on clean grease free slides, briefly fixed in meth-
anol and subsequently stained with May-Grunwald fol-
lowed by Giemsa. Approximately 5000 bone marrow
cells, comprising both polychromatic erythrocytes (PCE)
and normochromatic erythrocytes (NCE) were scored and
the ratios between PCE and NCE were calculated.
The mitotic index (MI) was determined from the same
slide which was scanned for MN. The non-dividing and
dividing cells were recorded and their ratios ascertained.
For sperm head anomaly (SHA), the epididymis of each
side of mouse of both (control and treated) sets was dis-
sected out and its inner content squeezed out into 10 mlBMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
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of 0.87% normal saline separately. It was made free of
fats, vas deferens and other tissues. The content was thor-
oughly shaken, filtered through a silken cloth and
dropped on grease free clean slides. The slides were al-
lowed to air dry and then stained by dilute Giemsa (1 ml
Giemsa in 10 ml distilled water).
Biochemical assays
Mice were sacrificed and their liver, spleen and kidney
were quickly isolated. The tissues were homogenized with
cold 0.87% normal saline, followed by centrifugation at
3000 g for 20 minutes in cooling centrifuge (C24, Remi
Instruments). Before carrying out the enzymatic estima-
tions the quantitative estimation of total protein was
made by the method of Lowry et al[7]. To 0.1 ml of the
sample, 0.9 ml of 0.1 (N) NaOH was added. Then 5 ml of
alkaline solution was added to the sample solution fol-
lowed by 0.5 ml of Folin-Phenol reagent and after 30 min-
utes the extinction was read at 750 nm against appropriate
blank in spectrophotometer (Shimadzu, Double beam
Spectrophotometer UV-180, Japan).
Estimation of Lipid Peroxidase
The lipid peroxidation was estimated from the superna-
tant by the method of Buege and Aust [8]. 1 ml of sample
(homogenate containing 0.1–0.2 mg of protein) was
mixed thoroughly with 2 ml of TCA-TBA-HCl (15% w/v
TCA and 0.375% w/v TBA in 0.25 N HCl,). The absorb-
ance of the sample was determined at 535 nm in a double
beam spectrophotometer against a suitable blank The
malonaldehyde concentration of the sample was calculat-
ed by using extinction coefficient of 1.56 ×  105 M-1cm-1.
Estimation of Acid and Alkaline Phosphatases
For the study of acid and alkaline phosphatases method of
Walter and Schutt [9] was followed. For acid phosphatase,
to 0.2 ml tissue homogenate 1 ml of acid buffer was added
to make the volume 1.2 ml. It was mixed and incubated at
37°C for 30 minutes. Then 2 ml of 0.1 (N) NaOH was
added. The absorbance was measured at 405 nm against a
blank. Then the activity of acid phosphatase was calculat-
ed as mM phenol liberated per mg of protein after 30 min
of incubation at 37°C using suitable standard curve.
For alkaline phosphatase activity the 0.05 ml homogenate
was mixed with 2 ml alkaline buffer so that the volume al-
ways stood at 2.05 ml. It was incubated at 37°C for 30
minutes, then 10 ml of 0.05 N NaOH was added and the
absorbance was measured at 405 nm against a blank. The
activity of alkaline phosphatase was calculated as mM
phenol liberated per mg of protein after 30 min of incuba-
tion at 37°C using suitable standard curve.
Statistical analysis and scoring of data
The significance test between different series of data was
conducted by student's t-test. During preparation of slides
for cytogenetical observation and biochemical estimation
of the different enzymes, the "observer" was kept "blind-
ed" in order to remove any "bias" in observation and to
keep uniformity in scoring data of both treated and con-
trol sets of mice.
Results
Out of the total number of 45 mice fed with p-DAB plus
PB and sacrificed at three fixation intervals, livers in some
27 mice showed distinct sign of tumor formation in the
form of pale reddish multiple nodules (some other rele-
vant histo-pathological data of liver in p-DAB+PB treated
and untreated control mice also provided in table-1),
while the remaining ones did not develop such nodules.
All mice fed p-DAB plus PB but no homeopathic drug de-
veloped tumorous nodules in liver and also had apprecia-
bly enlarged spleen. However, every 2 out of 5 mice that
received either Ch-30 or Ch-200 alongside p-DAB plus PB
did not show tumorous nodules, although they had
slightly enlarged spleen. Thus, in the present experiment
there was an overall 40% decline in the occurrence of tu-
mors owing to the treatment of Ch-30 and Ch-200.
Table 1: Showing some salient changes in liver histology of p-DAB+PB treated mice (showing tumors) as compared to untreated 
controls
p-DAB + PB treated series showing tumors Normal control series without tumor
In majority of cells, more than one nucleus per cell present, some nuclei very large Generally one nucleus per cell present
Vacuolated cytoplasm and loss of distinct cell outline in most cells, Cytoplasm not vacuolated
The number of hepatocytes, bile and duct cells increased Number of hepatocytes bile and duct cells relatively few
The spaces between adjacent cells not well-defined Cell outline distinct and spaces between adjacent cells well-
definedBMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
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Figure 1
a-m: Photomicrographs of metaphase complements showing normal set of chromosomes (la), and chromosome aberrations
like break (B, 1b), acentric fragment (AF, 1c), terminal association (TA, 1d), ring (R, 1e), centric fusion and precocious centro-
meric separation (If), C mitosis (1g) polyploidy (1h); sperm with normal (1i), and abnormal (1j-1k) head morphology; normo-
(1l), and poly- (1m) chromatic erythrocytes. Bar represents 10 µm.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
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Cytogenetical Studies
As compared to normal metaphase plates (Fig-1a) which
did not normally reveal any aberrations, various types of
chromosome aberrations of both major (Figs.
1b,1c,1d,1e,1h) and minor nature (Fig. 1f,1g) were en-
countered in certain metaphase plates of mice that re-
ceived p-DAB and/or PB treatments (see table 2). The total
frequencies of aberrations were found to be maximum in
the p-DAB and PB fed mice and the aberrations were con-
siderably reduced in both the drug fed series (Fig. 2).
However while Ch-30 appeared to protect the bone mar-
row cells at a higher scale at 60 and 90 days, Ch-200
showed greater protection at 120 days (p < 0.001; see ta-
ble 2). The mice fed PB alone had less number of chromo-
some aberrations than in the p-DAB + PB treated series
and differences in the % of the CA, when compared with
that of the normal controls were found to be statistically
significant at 90 (p < 0.05) and 120 days (p < 0.01).
Micronucleated erythrocytes
Data on occurrence of micronuclei in polychromatic (Fig.
1m) erythrocytes (PCE) and normochromatic (Fig. 1l)
erythrocytes (NCE) have been provided in table 2. The
percentages of MN were highest in the p-DAB and PB fed
mice. Both Ch-30 and 200 feeding reduced the occurrence
of MN. Ch-200 showed more pronounced action (p <
0.05) at 60 and 120 days (Fig. 3). PB itself produced a few
micronucleated erythrocytes not significantly different
from that of normal controls (table-2).
Mitotic index
In both Ch-30 and 200 fed mice, the MI was much less
than in the p-DAB plus PB fed mice and the protection
was statistically significant (p < 0.05 through p < 0.001).
The mitotic index in the PB fed mice was only slightly
more than in the normal control series (table-2, Fig. 4).
Sperm head anomaly
As against sperm with normal head morphology (Fig. 1i),
quite high incidence of sperm showing some form of ab-
normal head morphology (Fig. 1j,1k) has been recorded
in the different treatment series (see table 2, Fig. 5). Both
Ch-30 and Ch-200 reduced considerably the percentages
of sperm with abnormal head morphology and the differ-
ences were statistically significant (p < 0.05 through p <
0.001). The feeding of PB alone also produced abnormal
sperm in greater number than in the normal control and
the differences were statistically significant at 60 days (p <
0.05) and at 120 days (p < 0.01).
Lipid peroxidase activity
The lipid peroxidase activity was the highest in all the
three tissues at all fixation intervals in the p-DAB+ PB
treated series except at 90 and 120 days in the liver where
the activity was the highest in the p-DAB + PB+Ch-200 fed
mice (Fig. 6). However, interestingly enough, while the li-
pid peroxidase enzyme activity was generally much re-
duced in the Ch-200 fed mice as compared to Ch-30 fed
mice in spleen and kidney, the lower micro dose i.e. Ch-
30 appeared to reduce the activity in liver (p < 0.05) more
than that of Ch-200 at all fixation intervals (p < 0.01 to p
< 0.001, see table 3). The feeding of PB alone produced
similar or marginally increased activity in spleen, kidney
and liver at 60 and 90 days but the activity became appre-
ciably higher in the liver and kidney at 120 days but not
in the spleen.
Alkaline phosphatase activity
The alkaline phosphatase activity (AlkPA) in the p-DAB +
PB fed mice was highest in spleen and liver at all the three
fixation intervals while the activity declined in both Ch-30
and Ch-200 fed mice (p < 0.05, p < 0.001, see table-3, Fig.
7). Ch-200 showed greater efficacy in reducing AlkPA
than that of Ch-30 fed mice except at 90 days in case of
spleen. In the kidney, however, although p-DAB + PB
showed, except for a few cases, a high degree of AlkPA at
all fixation intervals, the activity could not be reduced by
Ch-200 till at 120 day (p < 0.05) while the activity level
became actually higher at 60 and 90 days. However, Ch-
30 could reduce the activity to some extent at all the fixa-
tion intervals although the differences were not statistical-
ly significant.
Acid phosphatase activity
The acid phosphatase activity (AcPA) in spleen, liver and
kidney was very high in p-DAB + PB fed mice and the ac-
tivity was slightly declined in the Ch-30 and Ch-200 fed
mice except at some fixation intervals where actually it
was higher than in the p-DAB + PB fed mice. The differ-
ences were not statistically significant in most cases and
only some favorable modulation was noted in liver and
kidney at 120 days (p < 0.05, p < 0.001; see table 3, Fig. 8).
Discussion
It had earlier been conclusively demonstrated that feeding
of carcinogenic azo dyes produced liver damage followed
by regeneration of parenchymal cells, proliferation of bile
ducts and connective tissue, and at later stages tumors de-
veloped from liver parenchyma that ended up with neo-
plastic characteristics [10]. Further, it was also
demonstrated that dietary PB had positive carcinogenic ef-
fect only when fed with the azodye 2-methyldiaminoa-
zobenzene, but neither of these two when fed alone
showed positive hepatocarcinogenesis in both mice and
rat [11,12]. It is generally accepted that covalent binding
of the metabolites of p-DAB (e.g. MAB, AAB etc.) with
DNA is a major carcinogenic factor [13]. In the present
study, the only PB fed mice also did not develop tumors
in liver, while those fed with p-DAB + PB developed tu-
mors. However, interestingly enough, every 2 out of 5B
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Table 2: Showing frequency distribution of mitotic indices (Ml) in 5000 cells, chromosome aberration (CA) in 500 cells, micronuclei (MN) in polychromatic (PCE) and normo-
chromatic (NCE) erythrocytes in 5000 cells and sperm head anomaly (SHA) in 5000 sperm in mice treated with p-Dimethylaminoazobenzene (DAB) + Phenobarbital (PB), DAB 
+ PB + Chelidonium (Ch)-30 and DAB + PB + Chelidonium (Ch)-200 and their Phenobarbital treated and normal controls. Equal number of cells/sperms observed from each of 
5 mice of a set.
Mitotic Index Chromosome Aberration Micronucleated Erythrocytes Sperm Head
Anomaly
Fixation
intervals
(days)
Series % of Ml
(% ± SE)
% of
Prot.
% of
Major
CA
% of
Other
CA
Total CA
(% ± SE)
% of
Prot.
% of
MN in
PCE
% of
MN in
NCE
P/N Total MN
(% ± SE)
% of
Prot.
Total SHA
(% ± SE)
% of
Prot.
Normal 1.32 ± 0.08 1.4 1.4 2.80 ± 0.58 0.04 0.26 0.89 0.16 ± 0.05 0.44 ± 0.12
PB 2.10 ± 0.48 1.6 1.8 3.40 ± 0.98 0.14 0.28 0.74 0.16 ± 0.05 1.08 ± 0.24
60 DAB + PB 8.70 ± 0.79 5.4 10.4 15.8 ± 2.11 0.53 0.88 0.84 0.72 ± 0.14 2.62 ± 0.28
DAB + PB + Ch-30 4.66 ± 0.34 4.04b 4.4 4.6 9.0 ± 0.78 6.8a 0.41 0.61 0.79 0.52 ± 0.09 0.20 1.66 ± 0.30 0.96a
DAB + PB + Ch-200 3.36 ± 0.37 5.34c 4.6 8.2 12.8 ± 3.87 3.0 0.45 0.26 0.497 0.32 ± 0.08 0.42a 0.8 ± 0.11 1.82c
Normal 1.32 ± 0.08 1.4 1.4 2.80 ± 0.58 0.04 0.26 0.89 0.16 ± 0.05 0.44 ± 0.12
PB 1.58 ± 0.14 2.2 3.0 5.20 ± 0.86 0.13 0.22 0.83 0.180.08 0.52 ± 0.09
90 DAB + PB 6.40 ± 1.14 6.6 4.2 10.8 ± 1.20 1.17 0.27 0.80 0.67 ± 0.10 2.90 ± 0.27
DAB + PB + Ch-30 3.08 ± 0.29 3.3a 4.4 4.8 9.20 ± 1.86 1.6 0.24 0.55 1.33 0.37 ± 0.10 0.16 2.20 ± 0.26 0.70
DAB + PB + Ch-200 2.90 ± 0.34 3.5a 4.6 5.6 10.2 ± 1.56 0.6 0.29 0.48 1.16 0.38 ± 0.11 0.16 1.66 ± 0.16 1.24b
Normal 1.32 ± 0.08 1.4 1.4 2.80 ± 0.58 0.04 0.26 0.89 0.16 ± 0.05 0.44 ± 0.12
PB 2.12 ± 0.30 2.4 4.2 6.60 ± 0.93 0.21 0.11 0.91 0.16 ± 0.08 1.12 ± 0.12
120 DAB + PB 8.20 ± 0.26 8.6 13.0 22.4 ± 0.25 0.63 0.54 0.80 0.58 ± 0.15 1.58 ± 0.31
DAB + PB + Ch-30 8.72 ± 0.65 -0.52 7.8 7 14.8 ± 2.18 7.6b 0.49 0.27 0.34 0.32 ± 0.08 0.32 0.40 ± 0.12 1.18b
DAB + PB + Ch-200 6.44 ± 0.35 1.8b 3.8 4.2 8.0 ± 0.32 14.4c 0.12 0.19 2.18 0.14 ± 0.06 0.43a 0.38 ± 0.07 1.20b
Major Types of CA include: Break; Centric fusion; Translocation; Fragment; Pulverisation; Ring; Terminal association; Polyploidy.;Aneuploidy. Other types of CA include: Erosion, Constric-
tion, Precocious centromeric separation, Centromericstrecthing, Stickiness, C-mitotic effect. SE= standard error, a= p < 0.05, b= p < 0.01, c= p < 0.001. Prot.= Protection given by the drugBMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
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mice, that is, about 40% of mice that received both p-DAB
and PB along with either Ch-30 or Ch-200 did not devel-
op tumors in liver while all mice fed p-DAB plus PB, but
no Chelidonium developed tumors. This seems to be a
dramatic finding as neither of these potentized drugs Ch-
30 or Ch-200 had literally a single molecule of original
drug substance in their diluted forms and were yet capable
of reducing/delaying tumor growth in mice. Such agents
that can antagonise or render protection at various levels
of carcinogenesis are always considered very important,
particularly so when they can be administered in micro
doses and they do not have any ill-effects/side-effects of
their own. When microdoses of either of these drugs were
fed alone to healthy mice in similar doses, and dissected
at corresponding fixation intervals, no tumor was found
in their liver, nor was any genotoxic effect found from the
assay of their chromosomes, sperm heads, or micronuclei.
Earlier, Roberfroid et al[14] reported that micro doses of
PB 9C positively reduced the incidence of tumors and
mortality in rats chronically fed with another carcinogen
Acetylamino fluorine along with PB. However, these au-
thors did not consider any of the protocols used in the
present study. Fisher [15] reported that the DNA repair
mechanisms of cultured mammalian cells in vitro could be
stimulated by very small doses of mutagens while working
with human lymphocytes.
Extensive toxicological investigations have now estab-
lished that increase in lipid peroxidation, alkaline and
acid phosphatase activities along with decreased level of
glutathione actually denote cytotoxicity and hepatocellu-
lar dysfunction [16–19]. The favorable modulations of
some of these enzymes, chromosomal and sperm head
damages noted in the Chelidonium fed mice as compared
to drug unfed p-DAB plus PB fed mice were very signifi-
cant. Thus it was suggestive that the micro doses of Ch i.e.
30 and 200 had positive protective effects against tumors
induced by p-DAB plus PB, and that Ch-200 appeared to
have marginally better effects at the longer intervals. Inci-
dentally, the efficacy of serial agitated dilutions of home-
Figure 2
Showing % of CA in different series of mice at different fixa-
tion intervals.
Figure 3
Showing % of MNE in different series of mice at different fix-
ation intervals.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
Page 8 of 12
(page number not for citation purposes)
opathic drugs in experimental toxicology had also been
convincingly advocated by meta-analysis done by Linde et
al[20].
p-DAB and its metabolites have been reported to cause ox-
idative DNA damage [13], which could also be attributa-
ble to the various types of chromosome aberrations
encountered in the present investigation. The formation
of adducts, DNA-copper-hydroperoxo complexes, etc as
suggested by Ohnishi et al[13], could also play an impor-
tant role in the carcinogenic processes of p-DAB. There-
fore antagonism in an unknown manner to either
formation of various metabolites of p-DAB or else in their
formation of adducts in DNA could have been one of the
major ways by which the potentized Chelidonium acted
in the mice treated with the azo dye to reduce the chromo-
somal damage.
It is difficult to understand precisely at the present state of
our knowledge how the ultra low doses of Chelidonium
could achieve such spectacular protective changes which
were amply demonstrable in the present study with the
different protocols used. One hypothesis to explain the
possible mechanism of action of the micro doses could be
as follows. Since these low doses of the medicines were
administered orally, their actions could possibly be medi-
ated through the receptor systems located on tongue and
the oral cavity. The drugs must have emanated specific sig-
nals in the receptor cells that could activate specific region
of brain (presumably hypothalamus) in a manner that
could possibly help elicit further signals to activate or re-
press certain transcriptional activities of specific regions of
DNA meant for restoration of the damages caused due to
the carcinogenic interaction. One way to test this hypoth-
esis can be either to measure the activity of the signal
transduction system through estimation of secondary
messenger (i.e cyclic AMP) or else to block the pathway se-
Figure 4
Showing % of MI in different series of mice at different fixa-
tion intervals.
Figure 5
Showing % of SHA in different series of mice at different fixa-
tion intervals.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
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lectively after use of any drug in such microdoses. Inciden-
tally, when some potentized homeopathic drugs were
used along with Actinomycin D, a transcription blocker,
the homeopathic drugs failed to elicit the desired protec-
tive levels against chromosomal and other cytogenetical
damages produced by arsenic intoxication and by ultra-
sonic sound waves [21,22] as compared to when the drugs
were administered alone (i.e. without Actinomycin-D).
Thus the repair mechanisms were essentially mediated
through active gene action. Khuda Bukhsh [23] proposed
a hypothesis to explain the possible mechanism of action
of such micro doses based on many circumstantial evi-
dences [21–33] that the micro doses act through the regu-
lation of relevant gene expression by eliciting impulses
similar to that of some hormones and enzymes. That can
suitably explain the mechanisms involved in the repair of
damaged chromosomes or sperm head by the application
of the micro doses. This can also explain the antagonizing
action against tumorigenesis/carcinogenesis which is es-
sentially a multi-gene and multi-step process in majority
of cancer including hepatocarcinoma [34]. Since the acti-
vation of proto-oncogene to oncogene is the key event for
the transformation of the normal hepatocyte to a malig-
nant liver tumor cell and that this process is controlled by
the interactions of many tumorigenic and tumor supres-
sor genes (e.g. p53 gene), it may be speculated that the mi-
Figure 6
Showing lipid peroxidase activity in liver of experimental
mice at different fixation intervals.
Figure 7
Showing alkaline phosphatase activity in liver of experimental
mice at different fixation intervals.B
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Table 3: Mean activities of lipid peroxidase (nMol MDA/gm wet tissue), acid and alkaline phosphatase activities (in terms of mM Phenol liberated/100 mg protein after 30 min of 
incubation at 37°C), in different organs of mice treated with p Dimethylaminoazobenzene (DAB) + Phenobarbital (PB), DAB + PB + Chelidonium (Ch)-30 and DAB + PB + Che-
lidonium (Ch)-200 against their normal and phenobarbital control.
Lipid peroxidase activity Alkaline phosphatase activity Acid phosphatase activity
Fixation
Interval
(Days)
Series Liver Kidney Spleen Liver Kidney Spleen Liver Kidney Spleen
Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot. Activity
± SE
% Prot.
Normal 18.72 ± 1.27 16.67 ± 0.26 25.44 ± 0.68 0.09 ± 0.01 0.12 ± 0.03 0.09 ± 0.01 0.10 ± 0.002 0.09 ± 0.004 0.10 ± 0.003
PB 16.58 ± 0.43 15.85 ± 1.39 17.35 ± 0.45 0.11 ± 0.001 0.11 ± 0.004 0.11 ± 0.002 0.18 ± 0.02 0.15 ± 0.02 0.15 ± 0.02
60 DAB +PB 117.48 ± 3.80 134.41 ± 1.08 207.95 ± 3.01 0.28 ± 0.04 0.25 ± 0.02 0.15 ± 0.01 0.30 ± 0.03 0.29 ± 0.05 0.27 ± 0.04
DAB+PB+Ch30 24.26 ± 0.78 93.22a 29.04 ± 1.05 105.37c 44.32 ± 1.14 163.63b 0.11 ± 0.03 0.17 0.22 ± 0.01 0.03 0.07 ± 0.03 0.07a 0.30 ± 0.03 0 0.30 ± 0.05 0.01 0.26 ± 0.03 0.01
DAB+PB+Ch200 84.67 ± 0.27 32.81 19.737 ± 0.45 114.67 48.71 ± 3.28 159.24b 0.05 ± 0.03 0.22 0.28 ± 0.04 0.04 ± 0.01 0.11 0.24 ± 0.03 0.06 0.22 ± 0.04 0.07 0.30 ± 0.03 0.03
Normal 18.72 ± 1.27 15.85 ± 1.39 25.44 ± 0.68 0.09 ± 0.01 0.12 ± 0.03 0.09 ± 0. 01 0.10 ± 0.002 0.09 ± 0.004 0.10 ± 0.003
PB 25.21 ± 0.31 16.58 ± 0.62 21.88 ± 0.98 0.11 ± 0.002 0.12 ± 0.003 0.11± 0. 003 0.19 ± 0.003 0.18 ± 0.01 0.18 ± 0.003
90 DAB +PB 69.25 ± 0.75 61.42 ± 0.61 91.99 ± 5.20 0.24 ± 0.04 0.27 ± 0.04 0.17± 0. 01 0.36 ± 0.04 0.30 ± 0.01 0.24 ± 0.02
DAB+PB+Ch30 48.77 ± 3.07 20.48 22.12 ± 0.76 39.30c 30.95 ± 3.36 61.04c 0.04 ± 0.01 0.19 0.26 ± 0.05 0.01 0.06 ± 0. 04 0.11a 0.32 ± 0.07 0.04 0.29 ± 0.04 0.01 0.28 ± 0.04 0.04
DAB+PB+Ch200 135.74 ± 0.22 -66.49 22.18 ± 0.64 39.24b 30.49 ± 0.75 61.51c 0.14 ± 0.06 0.09 0.34 ± 0.02 0.09 ± 0. 04 0.08 0.30 ± 0.04 0.06 0.29 ± 0.02 0.01 0.30 ± 0.04 0.06
Normal 18.72 ± 1.27 15.85 ± 1.39 25.435 ± 0.68 0.09 ± 0.01 0.12 ± 0.03 0.09 ± 0. 01 0.10 ± 0.002 0.09 ± 0.004 0.10 ± 0.003
PB 38.63 ± 2.79 44.96 ± 1.49 28.72 ± 0.65 0.14 ± 0.003 0.12 ± 0.01 0.17 ± 0. 002 0.20 ± 0.001 0.15 ± 0.01 0.18 ± 0.001
120 DAB+PB 165.43 ± 1.92 138.65 ± 2.09 274.55 ± 1.08 0.19 ± 0.02 0.31 ± 0.02 0.15 ± 0. 02 0.40 ± 0.07 0.34 ± 0.05 0.29 ± 0.03
DAB+PB+Ch30 113.04 ± 1.14 52.39a 89.79 ± 0.48 48.86 92.56 ± 0.18 181.99c 0.19 ± 0.003 0.001 0.27 ± 0.05 0.04 0.15 ± 0. 003 0.01 0.50 ± 0.05 0.1 0.67 ± 0.09 0.33 0.22 ± 0.05 0.06
DAB+PB+Ch200 190.25 ± 0.48 -25.82 18.21 ± 0.48 120.45b 110.51 ± 0.36 160.04c 0.08 ± 0.01 0.102 0.15 ± 0.06 0.16a 0.10 ± 0. 01 0.05a 0.28 ± 0.02 0.12a 0.16 ± 0.02 0.17 0.24 ± 0.01 0.05
SE= Standard error, a =p < 0.05, b= p < 0.01, c= p < 0.001. Prot. = Protection given by the drug.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/4
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cro doses of the drug might have interfered with the
process of carcinogenesis either by actively modifying ac-
tion of certain of these genes responsible for the transfor-
mation of cells to cancerous ones by release of specific
transcription factors, or else by activating certain tumor-
suppressor genes in an unknown manner. A careful study
of telomerase activity in these experimental mice can also
be helpful in understanding the underlying genetic mech-
anism. In fact the modulating effects of the drug on resto-
ration of damage caused to several gene regulated
phenomena like enzyme activities, chromosome and
sperm structure etc would further strengthen the conten-
tion that these drugs possibly acted through regulatory ac-
tions on a number of key genes, related not only to the
structure and normal functioning of liver hepatocytes, but
also to the ones meant for maintaining integrity of bone
marrow chromosomes and sperm head.
Conclusion
From the present investigation, it becomes evident that ul-
tra-low doses of the homeopathic drug Chelidonium are
also capable of rendering anti-tumor and anti-genotoxic
activities against azo-dye induced hepatocarcinoma in
mice. This would encourage their use even in cancerous
liver disorders with greater degree of assurance of their ef-
ficacy. Further, it would hopefully open up new vistas for
understanding the little known mechanism of action of
the homeopathic microdoses which in many instances do
not even contain a single molecule of the original drug
substance.
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